PINK
WUXAY

WuXi AppTec Co. Ltd

Diagnostics & Research
Healthcare

Prices are adjusted according to historical splits.

WuXi AppTec Co. Ltd Stock Price

Vitals

Today's Low:
$10.49
Today's High:
$10.66
Open Price:
$10.5214
52W Low:
$7.38
52W High:
$17.7639
Prev. Close:
$10.1518
Volume:
1359

Company Statistics

Market Cap.:
$35.67 billion
Book Value:
15.905
Revenue TTM:
$39.35 billion
Operating Margin TTM:
24.77%
Gross Profit TTM:
$14.68 billion
Profit Margin:
22.4%
Return on Assets TTM:
10.17%
Return on Equity TTM:
20.78%

Company Profile

WuXi AppTec Co. Ltd had its IPO on under the ticker symbol WUXAY.

The company operates in the Healthcare sector and Diagnostics & Research industry. WuXi AppTec Co. Ltd has a staff strength of 0 employees.

Stock update

Shares of WuXi AppTec Co. Ltd opened at $10.52 at the start of the last trading session i.e. 2023-03-23.

The stocks traded within a range of $10.49 - $10.66, and closed at $10.66.

This is a +5.01% increase from the previous day's closing price.

A total volume of 1,359 shares were traded at the close of the day’s session.

In the last one week, shares of WuXi AppTec Co. Ltd have increased by +6.61%.

WuXi AppTec Co. Ltd's Key Ratios

WuXi AppTec Co. Ltd has a market cap of $35.67 billion, indicating a price to book ratio of 4.6305 and a price to sales ratio of 0.9452.

In the last 12-months WuXi AppTec Co. Ltd’s revenue was $39.35 billion with a gross profit of $14.68 billion and an EBITDA of $11.24 billion. The EBITDA ratio measures WuXi AppTec Co. Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, WuXi AppTec Co. Ltd’s operating margin was 24.77% while its return on assets stood at 10.17% with a return of equity of 20.78%.

In Q3, WuXi AppTec Co. Ltd’s quarterly earnings growth was a negative -5.7% while revenue growth was a positive 71.8%.

WuXi AppTec Co. Ltd’s PE and PEG Ratio

Forward PE
19.802
Trailing PE
24.2273
PEG

Its diluted EPS in the last 12-months stands at $0.44 per share while it has a forward price to earnings multiple of 19.802 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into WuXi AppTec Co. Ltd’s profitability.

WuXi AppTec Co. Ltd stock is trading at a EV to sales ratio of 0.9451 and a EV to EBITDA ratio of 3.072. Its price to sales ratio in the trailing 12-months stood at 0.9452.

WuXi AppTec Co. Ltd stock pays annual dividends of $0 per share, indicating a yield of 0.84% and a payout ratio of 21.89%.

Balance sheet and cash flow metrics

Total Assets
$65.75 billion
Total Liabilities
$17.47 billion
Operating Cash Flow
$-2120854885.00
Capital Expenditure
$2.33 billion
Dividend Payout Ratio
21.89%

WuXi AppTec Co. Ltd ended 2023 with $65.75 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $65.75 billion while shareholder equity stood at $44.81 billion.

WuXi AppTec Co. Ltd ended 2023 with $1.69 billion in deferred long-term liabilities, $17.47 billion in other current liabilities, 2960419498.00 in common stock, $18.40 billion in retained earnings and $1.93 billion in goodwill. Its cash balance stood at $9.21 billion and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $880.28 million.

WuXi AppTec Co. Ltd’s total current assets stands at $25.46 billion while long-term investments were $0 and short-term investments were $70.20 million. Its net receivables were $7.32 billion compared to accounts payable of $1.84 billion and inventory worth $6.58 billion.

In 2023, WuXi AppTec Co. Ltd's operating cash flow was $-2120854885.00 while its capital expenditure stood at $2.33 billion.

Comparatively, WuXi AppTec Co. Ltd paid $0.22 in dividends in 2023.

Other key metrics

Current Trading Price
$10.66
52-Week High
$17.7639
52-Week Low
$7.38
Analyst Target Price
$

WuXi AppTec Co. Ltd stock is currently trading at $10.66 per share. It touched a 52-week high of $17.7639 and a 52-week low of $17.7639. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $11.67 and 200-day moving average was $10.94 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About WuXi AppTec Co. Ltd

The stock symbol (also called stock or share ticker) of WuXi AppTec Co. Ltd is WUXAY

The IPO of WuXi AppTec Co. Ltd took place on

Similar Industry Stocks (Diagnostics & Research)

Last Price
Chg
Chg%
GeoPark Ltd (GPRK)
$10.48
-0.16
-1.5%
$4.97
0.12
+2.47%
$10.09
0.09
+0.9%
$9.73
0.27
+2.85%
$1.23
-0.05
-3.91%
$1.02
0.01
+0.98%
$0.2
-0
-0.65%
$1.09
-0.01
-1.36%
$3.35
-0.18
-5.1%
$2.07
0.1
+4.82%

Most Active

Last Price
Chg
Chg%
$0.11
-0.01
-6.33%
$0
-0
-20%
Boxed Inc (BOXD)
$0.34
0.16
+91.28%
$0
0
+100%
Tesla Inc (TSLA)
$192.22
1.07
+0.56%

Top Gainers

Last Price
Chg
Chg%
$0
0
+58723.53%
$0
0
+20460.42%
$0.63
0
+2548.22%
$0.02
0
+1566.67%

Top Losers

Last Price
Chg
Chg%
$0
-0.01
-98.52%
NGC-WT (NGC-WT)
$0
-0.04
-94.66%
$4.7
-33.3
-87.63%
Imara Inc (IMRA)
$21
0
-78.71%

About

WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People’s Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People’s Republic of China.

Address

288 Fute Zhong Road, Shanghai, China, 200131